Terms: = Prostate cancer AND ACVR2A, ACVR2, 92, ENSG00000121989, ACTRII, P27037
4637 results:
1. Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
Rosar F; Burgard C; David S; Marlowe RJ; Bartholomä M; Maus S; Petto S; Khreish F; Schaefer-Schuler A; Ezziddin S
Sci Rep; 2024 May; 14(1):11271. PubMed ID: 38760451
[TBL] [Abstract] [Full Text] [Related]
2. CYP7B1 as a Biomarker for prostate cancer Risk and Progression: Metabolic and Oncogenic Signatures (Diagnostic Immunohistochemistry Analysis by Tissue Microarray in prostate cancer Patients-Diamond Study).
Russo GI; Durukan E; Asmundo MG; Lo Giudice A; Salzano S; Cimino S; Rescifina A; Fode M; Abdelhameed AS; Caltabiano R; Broggi G
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731981
[TBL] [Abstract] [Full Text] [Related]
3. Vikil
Tettey CO; Essuman EK; Aninagyei E; Kwansa-Bentum HT; Agyemang Boakye A; Kortei NK; Boamah D
Integr Cancer Ther; 2024; 23():15347354241253846. PubMed ID: 38721848
[TBL] [Abstract] [Full Text] [Related]
4. Faster both in operative time and functional recovery by the extraperitoneal daVinci SP-based robot-assisted radical prostatectomy: a propensity score matching analysis compared to transperitoneal multiport counterpart.
Ko YH; Jang JY; Kim YU; Kim SW
J Robot Surg; 2024 May; 18(1):205. PubMed ID: 38714543
[TBL] [Abstract] [Full Text] [Related]
5. Predicting clinically significant prostate cancer following suspicious mpMRI: analyses from a high-volume center.
Jahnen M; Hausler T; Meissner VH; Ankerst DP; Kattan MW; Sauter A; Gschwend JE; Herkommer K
World J Urol; 2024 May; 42(1):290. PubMed ID: 38702557
[TBL] [Abstract] [Full Text] [Related]
6. On the necessity of specialized knowledge-based models for SBRT prostate treatments plans.
Scaggion A; Cavinato S; Dusi F; El Khouzai B; Guida F; Paronetto C; Rossato MA; Sapignoli S; Scott ASA; Sepulcri M; Paiusco M
Phys Med; 2024 May; 121():103364. PubMed ID: 38701626
[TBL] [Abstract] [Full Text] [Related]
7. Identification and Quantification of Radiotherapy-related Protein Expression in cancer Tissues Using the Qupath Software and Prediction of Treatment Response.
Hasegawa T; Someya M; Tsuchiya T; Kitagawa M; Fukushima Y; Gocho T; Mafune S; Okuda R; Kaguchi J; Ohguro A; Kamiyama R; Ashina A; Toshima Y; Hirohashi Y; Torigoe T; Sakata KI
In Vivo; 2024; 38(3):1470-1476. PubMed ID: 38688633
[TBL] [Abstract] [Full Text] [Related]
8. Biomarker vs MRI-Enhanced Strategies for prostate cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
[TBL] [Abstract] [Full Text] [Related]
9. [Exploration and validation of optimal cut-off values for tPSA and fPSA/tPSA screening of prostate cancer at different ages].
Liu XM; Duan HY; Zhang DQ; Chen C; Ji YT; Zhang YM; Feng ZW; Liu Y; Li JJ; Zhang Y; Li CY; Zhang YC; Yang L; Lyu ZY; Song FF; Song FJ; Huang YB
Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):354-364. PubMed ID: 38644271
[No Abstract] [Full Text] [Related]
10. Racial Differences in Germline Genetic Testing Completion Among Males With Pancreatic, Breast, or Metastatic prostate cancers.
Shevach JW; Candelieri-Surette D; Lynch JA; Hubbard RA; Alba PR; Glanz K; Parikh RB; Maxwell KN
J Natl Compr Canc Netw; 2024 Apr; 22(4):237-243. PubMed ID: 38631387
[TBL] [Abstract] [Full Text] [Related]
11. Clinical and Radiological Factors for Predicting Clinically Significant prostate cancer in Biopsy-Naive Patients With PI-RADS 3 Lesions.
Zhang Z; Hu C; Lin Y; Song O; Gong D; Zhang X; Wang N
Technol Cancer Res Treat; 2024; 23():15330338241246636. PubMed ID: 38629205
[TBL] [Abstract] [Full Text] [Related]
12. Relevance of blood tumor markers in inpatients with significant involuntary weight loss and elevated levels of inflammation biomarkers.
Gronnier M; Hedhli K; Sauzay C; Salle V; Duhaut P; Schmidt J; Dernoncourt A
BMC Cancer; 2024 Apr; 24(1):468. PubMed ID: 38622530
[TBL] [Abstract] [Full Text] [Related]
13. A novel biopsy scheme for prostate cancer: targeted and regional systematic biopsy.
He Y; Fan Y; Song H; Shen Q; Ruan M; Chen Y; Li D; Li X; Liu Y; Zhang K; Zhang Q
BMC Urol; 2024 Apr; 24(1):85. PubMed ID: 38614971
[TBL] [Abstract] [Full Text] [Related]
14. [Difference between prostate cancer patients' Gleason scores from preoperative biopsy and those from postoperative pathology].
Zhao XD; Liu YH; Hu J; Wang ZH; Jin XX; Ma MF; Zhou YL; Chen YH; Cao J; Dong J; Xu S
Zhonghua Nan Ke Xue; 2023 May; 29(5):393-401. PubMed ID: 38602754
[TBL] [Abstract] [Full Text] [Related]
15. Is Unilateral Lymphadenectomy an Option in Selected Patients with prostate cancer?
Kassab BN; De Pablos-Rodríguez P; Ferrer ÁG; García AC; Fons AC; Aragón F; Ramón-Borja JC; Ramírez-Backhaus M
Arch Esp Urol; 2024 Mar; 77(2):129-134. PubMed ID: 38583004
[TBL] [Abstract] [Full Text] [Related]
16. prostate-Specific Antigen Screening and 15-Year prostate cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
Martin RM; Turner EL; Young GJ; Metcalfe C; Walsh EI; Lane JA; Sterne JAC; Noble S; Holding P; Ben-Shlomo Y; Williams NJ; Pashayan N; Bui MN; Albertsen PC; Seibert TM; Zietman AL; Oxley J; Adolfsson J; Mason MD; Davey Smith G; Neal DE; Hamdy FC; Donovan JL;
JAMA; 2024 May; 331(17):1460-1470. PubMed ID: 38581198
[TBL] [Abstract] [Full Text] [Related]
17. Patient-Reported Outcome Measures Following Hyperbaric Oxygen Therapy for Radiation Cystitis: Early Results From the Multicenter Registry for Hyperbaric Oxygen Therapy.
Moses RA; Hunter AE; Brandes ER; Zhang Z; Rees JR; Peacock JL; Bihrle W; Sethuraman K; Weaver LK; Buckey JC
J Urol; 2024 Jun; 211(6):765-774. PubMed ID: 38573938
[TBL] [Abstract] [Full Text] [Related]
18. Development of a multigenomic liquid biopsy (PROSTest) for prostate cancer in whole blood.
Modlin IM; Kidd M; Drozdov IA; Boegemann M; Bodei L; Kunikowska J; Malczewska A; Bernemann C; Koduru SV; Rahbar K
Prostate; 2024 Jun; 84(9):850-865. PubMed ID: 38571290
[TBL] [Abstract] [Full Text] [Related]
19. Prediction of false-positive PI-RADS 5 lesions on prostate multiparametric MRI: development and internal validation of a clinical-radiological characteristics based nomogram.
Cheng Y; Fan B; Fu Y; Yin H; Lu J; Li D; Li X; Qiu X; Guo H
BMC Urol; 2024 Apr; 24(1):76. PubMed ID: 38566091
[TBL] [Abstract] [Full Text] [Related]
20. Primary mucinous adenocarcinoma of the urethra: A contemporary clinicopathologic analysis of 17 patients.
Alrohaibani A; Osunkoya AO
Pathol Res Pract; 2024 Apr; 256():155273. PubMed ID: 38565023
[TBL] [Abstract] [Full Text] [Related]
[Next]
